The firm reported that it had not received any revenues in the quarter tied to system sales. It had announced separately yesterday that it will reposition its focus on the molecular diagnostics industry.
While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.
